Question 1

What specific treatments will I receive in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) clinical trial (NCT03989414). Contact the study team or your healthcare provider for specific answers.

Question 2

How does CC-92480 compare to my current treatment options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) clinical trial (NCT03989414). Contact the study team or your healthcare provider for specific answers.

Question 3

What are the potential side effects of the treatments in this study?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) clinical trial (NCT03989414). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to come in for visits and treatments?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) clinical trial (NCT03989414). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if my condition worsens while participating in the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) clinical trial (NCT03989414). Contact the study team or your healthcare provider for specific answers.

Question 6

How will my progress be monitored during the study?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) clinical trial (NCT03989414). Contact the study team or your healthcare provider for specific answers.

What this study is about